IFPMA is based in Geneva and is in official relations with the United Nations[2] where it contributes industry expertise to global health discussions.
[6] The code revision has been followed by Ethoscope[7] – an open-source, continuously evolving resource that contains diverse guidance designed to keep pace with emerging developments.
[8] Today over 35 IFPMA member companies contribute resources and knowhow to SDG initiatives [9] partnering with academia, development organizations, NGOs, foundations and other business sectors.
[11] A wide range of stakeholders across the public and private sectors have an opportunity to collaborate more closely to increase affordability of and access to essential medicines, and the low-cost, but highly effective, interventions and screenings.
[12] Since January 2025, the President of IFPMA is Dr Thomas Schinecker, CEO, Roche Group.